FDA Proposes Easing Access to Unproven Peptide Drugs, Report Says

The Food and Drug Administration (FDA) is preparing to implement a policy that could ease access to unproven peptide drugs, according to a report by The Associated Press. This move comes despite internal scientific assessments indicating that these drugs have not been adequately studied for safety and effectiveness, and may pose risks.

The proposed "Interim Access Policy" has been submitted for review by the White House, as indicated by a filing notice on an Office of Management and Budget website. While the specifics of the policy remain undisclosed, sources familiar with the proposal suggest it would grant the FDA "enforcement discretion." This would enable the agency to choose not to enforce existing regulations on certain peptides, thereby reassuring specialty pharmacies interested in producing them that they would not face regulatory action.

Peptide drugs have gained popularity, particularly within certain health movements. However, the FDA's own staff scientists have raised concerns, noting insufficient data to confirm their safety and efficacy. The potential for harm has been a significant point of contention raised by these internal reviews.

The Department of Health and Human Services, which oversees the FDA, has not yet responded to requests for comment regarding the proposed policy.